You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

REFRACTORY OR RELAPSED

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Refractory/Relapsed Autoimmune Hemolytic Anemia Trial in Tianjin (Zanubrutinib)

Not yet recruiting
  • Refractory/Relapsed Autoimmune Hemolytic Anemia
  • Tianjin, Tianjin, China
    Regenerative Medicine Center
Aug 27, 2023

Bortezomib, Acute Myeloid Leukemia Trial in Wuhan (DAG pre-excitation regimen with Bortezomib)

Recruiting
  • Bortezomib
  • Acute Myeloid Leukemia
  • DAG pre-excitation regimen with Bortezomib
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Jul 31, 2023

Relapse/Refractory Multiple Myeloma Trial in Hangzhou (DeepTag-GPRC5D Targeted CAR T-cells)

Recruiting
  • Relapse/Refractory Multiple Myeloma
  • DeepTag-GPRC5D Targeted CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Oct 10, 2023

Warm Autoimmune Hemolytic Anemia Trial in Beijing (Sirolimus)

Not yet recruiting
  • Warm Autoimmune Hemolytic Anemia
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Jun 21, 2023

Acute Myeloid Leukemia Trial in Beijing (Ven+CAG)

Recruiting
  • Acute Myeloid Leukemia
  • Beijing, Beijing, China
    Peking University People's Hospital
Jun 23, 2023

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

Recruiting
  • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
  • dualCAR-NK19/70 cell
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023

Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

Recruiting
  • Peripheral T Cell Lymphoma
  • +2 more
  • Chidamide combined with Duvillisib
  • Xiamen, Fujian, China
    The First Affiliated Hosptial of Xiamen University
Nov 28, 2023

Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)

Recruiting
  • Neuroblastoma
  • Naxitamab monotherapy
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 31, 2023

T-cell Acute Lymphoblastic Leukemia Trial in Beijing (CD5 CAR-T)

Recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • CD5 CAR-T
  • Beijing, Beijing, China
    Xuanwu Hospital Capital Medical University
Oct 23, 2022

Leukemia, Myeloid, Acute Trial (CD33KO-HSPC; CART33)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • CD33KO-HSPC; CART33
  • (no location specified)
Jul 13, 2023

Hodgkin Lymphoma Trial (favezelimab/pembrolizumab, bendamustine, gemcitabine)

Not yet recruiting
  • Hodgkin Lymphoma
  • favezelimab/pembrolizumab
  • +2 more
  • (no location specified)
Aug 18, 2022

B-cell Non Hodgkin Lymphoma Trial in Hanzhou (CB dualCAR-NK19/70)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • CB dualCAR-NK19/70
  • Hanzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Dec 25, 2022

CNS Lymphoma Trial in Nanchang (Human CD19-CD22 Targeted T Cells Injection)

Recruiting
  • Central Nervous System Lymphoma
  • Human CD19-CD22 Targeted T Cells Injection
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Dec 13, 2022

Relapse Multiple Myeloma, Refractory Multiple Myeloma Trial in Hangzhou (BCMA Targeted CAR T-cells)

Recruiting
  • Relapse Multiple Myeloma
  • Refractory Multiple Myeloma
  • BCMA Targeted CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Medical College, Zhejiang Univers
Jun 18, 2022

B-Cell Leukemia, B Cell Lymphoma Trial in Kunming (anti-CD19 UCAR-T injection)

Recruiting
  • B-Cell Leukemia
  • B Cell Lymphoma
  • anti-CD19 UCAR-T injection
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Apr 21, 2022

Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma Trial in Atlanta (Ex Vivo Expanded Allogeneic ?d T Cells in

Not yet recruiting
  • Neuroblastoma
  • +2 more
  • Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
  • Atlanta, Georgia
    Children's Healthcare of Atlanta
Oct 6, 2022

Auto/Allo Tandem Transplant for Relapsed B-NHL

Completed
  • Non Hodgkin Lymphoma
  • auto transplant followed by allo transplant
  • (no location specified)
Oct 24, 2022

Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial in Miami (Mosunetuzumab,

Not yet recruiting
  • Refractory Non-Hodgkin Lymphoma
  • +2 more
  • Miami, Florida
    University of Miami
Aug 3, 2022

Refractory Cancer, Relapsed Cancer Trial in Weston (Drug Sensitivity Test (DST))

Not yet recruiting
  • Refractory Cancer
  • Relapsed Cancer
  • Drug Sensitivity Test (DST)
  • Weston, Florida
    Lerner College of Medicine: Cleveland Clinic Florida
Sep 1, 2023

Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Köln, Germany
    Local Institution - 0017
Dec 4, 2023

Acute Myeloid Leukemia Trial in Nanjing (Chidamide, Cladribine)

Recruiting
  • Acute Myeloid Leukemia
  • Nanjing, Jiangsu, China
    Department of Hematology, Zhongda Hospital Southeast University,
Apr 23, 2022

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia Recurrent Trial in Beijing (CD123-CAR-NK cells)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia Recurrent
  • CD123-CAR-NK cells
  • Beijing, Beijing, China
    The Fifth Medical Center of Chinese People's Liberation Army (PL
Oct 24, 2022

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

Relapsed/Refractory Multiple Myeloma Trial in Suzhou (ICI201)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
Jul 31, 2023

B-cell Non Hodgkin Lymphoma Trial in Hanzhou (anti-CD19 CAR-NK)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • anti-CD19 CAR-NK
  • Hanzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jul 21, 2022